| Deleyrolle, Phuong |
| Completed | 2 | 175 | US | pp65-shLAMP DC with GM-CSF, pp65-shLAMP mRNA DCs with GM-CSF, unpulsed PBMC and saline, Peripheral Blood Mononuclear Cells, Td, Tetanus and Diphtheria Toxoid, Saline, Normal Saline, pp65-flLAMP DC with GM-CSF, pp65-flLAMP mRNA DCs with GM-CSF | University of Florida, National Cancer Institute (NCI) | Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV, GBM | 11/23 | 11/23 | | |
ADAGiO, NCT06254326: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients |
|
|
| Active, not recruiting | 1 | 12 | US | TTRNA-DC vaccines with GM-CSF, Autologous Hematopoietic Stem cells (HSCs), TTRNA-xALT, Td vaccine | University of Florida, Oligo Nation, Inc | Recurrent Oligodendroglioma, Progressive Oligodendroglioma | 12/27 | 06/28 | | |
NCT06389591: RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM) |
|
|
| Active, not recruiting | 1 | 24 | US | pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1), RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2) | University of Florida, National Cancer Institute (NCI) | Recurrent Glioblastoma | 12/27 | 12/28 | | |
IMPACT, NCT05353530: Phase I Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma |
|
|
| Recruiting | 1 | 18 | US | Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells, 8R-70CAR T cells | University of Florida, United States Department of Defense, AM Rosen Foundation | Glioblastoma Multiforme, Glioblastoma | 12/27 | 12/42 | | |
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors |
|
|
| Recruiting | N/A | 57 | Canada, US | Focused Ultrasound (Exablate Model 4000) | InSightec | Glioblastoma, Glioma, Liquid Biopsy | 12/24 | 03/25 | | |
NCT03671889: ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease |
|
|
| Recruiting | N/A | 150 | US | Blood Brain Barrier (BBB) Disruption, ExAblate Neuro | InSightec | Alzheimer Disease | 12/25 | 12/25 | | |
| Hilliard, Justin |
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors |
|
|
| Recruiting | N/A | 57 | Canada, US | Focused Ultrasound (Exablate Model 4000) | InSightec | Glioblastoma, Glioma, Liquid Biopsy | 12/24 | 03/25 | | |
NCT03671889: ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease |
|
|
| Recruiting | N/A | 150 | US | Blood Brain Barrier (BBB) Disruption, ExAblate Neuro | InSightec | Alzheimer Disease | 12/25 | 12/25 | | |
| Osborne, Joan |
NCT03671889: ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease |
|
|
| Recruiting | N/A | 150 | US | Blood Brain Barrier (BBB) Disruption, ExAblate Neuro | InSightec | Alzheimer Disease | 12/25 | 12/25 | | |
